Lack of association of A-6G polymorphism of AGT gene with essential hypertension in the Chinese population

Journal of Cardiovascular Medicine

Volumn 13, Issue 8, 2012, Pages 505-510

  Li, Yan Yan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

A 6G polymorphism; AGT gene; angiotensinogen; hypertension; meta analysis

Indexed keywords

ANGIOTENSINOGEN;

ARTICLE; CHINESE; DISEASE ASSOCIATION; ESSENTIAL HYPERTENSION; ETHNICITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; POPULATION GENETICS; SYSTEMATIC REVIEW;

ANGIOTENSINOGEN; ASIAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; POLYMORPHISM, GENETIC;

EID: 84864283132     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e328355a726     Document Type: Article

References (56)

1. Dickson ME, Sigmund CD. Genetic basis of hypertension: revisiting angiotensinogen. Hypertension 2006; 48:14-20. (Pubitemid 44297514)
2. Markovic D, Tang X, Guruju M, et al. Association of angiotensinogen gene polymorphisms with essential hypertension in African-Americans and Caucasians. Hum Hered 2005; 60:89-96. (Pubitemid 41540636)
3. Shim SS, Jun JK, Park JS, et al. Angiotensinogen G(-6)A polymorphism is associated with the elevation of blood pressure in the hypertensive disorders of pregnancy. Twin Res Hum Genet 2006; 9:76-80. (Pubitemid 43384796)
4. Fukamizu A, Takahashi S, Seo MS, et al. Structure and expression of the human angiotensinogen gene. Identification of a unique and highly active promoter. J Biol Chem 1990; 265:7576-7582.
5. Jeunemaitre X, Soubrier F, Kotelevtsev YV, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992; 71:169-180.
6. Hunt SC, Cook NR, Oberman A, et al. Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: trials of hypertension prevention, phase II. Hypertension 1998; 32:393-401. (Pubitemid 28429124)
7. Jain S, Tillinger A, Mopidevi B, et al. Transgenic mice with -6A haplotype of the human angiotensinogen gene have increased blood pressure compared with -6G haplotype. J Biol Chem 2010; 285:41172-41186.
8. Province MA, Boerwinkle E, Chakravarti A, et al. Lack of association of the angiotensinogen-6 polymorphism with blood pressure levels in the comprehensive NHLBI Family Blood Pressure Program. National Heart, Lung and Blood Institute. J Hypertens 2000; 18:867-876. (Pubitemid 30459488)
9. Pereira TV, Nunes AC, Rudnicki M, et al. Meta-analysis of the association of 4 angiotensinogen polymorphisms with essential hypertension: a role beyond M235T? Hypertension 2008; 51:778-783. (Pubitemid 351301535)
10. Li NF, Zhou L, Wu WD, et al. The relationship between the variants in 50upstream core promoter A (-6)G and A (-20) C of angiotensinogen gene and essential hypertension in Kazakans of Xinjiang. Chin J Med Genet 2004; 21:23-28. (Pubitemid 38202269)
11. Yang C, Qiu CC, Lu SD, et al. Association analysis of variants in the core promoter region of angiotensinogen gene with essential hypertension in Tibetan population. Chin J Med Genet 2000; 17:149-152. (Pubitemid 30423058)
12. Dronmatsering, Zhuang LP, Cui CY, et al. Genetic basis of essential hypertension in Tibet. Natl Med J China 2002; 82:1009-1012.
13. Wang JH, Lin CM, Wang LS, et al. Association between molecular variants of the angiotensinogen gene and hypertension in Amis tribes of eastern Taiwan. J Formos Med Assoc 2002; 101:183-188.
14. Liu Y, Jin W, Jiang ZW, et al. Relationship between six single nucleotide polymorphism of angiotensinogen gene and essential hypertension. Chin J Med Genet 2004; 21:116-119. (Pubitemid 38506619)
15. Cochran WG. The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics 1968; 24:295-313.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188. (Pubitemid 17189972)
17. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22:719-748.
18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634. (Pubitemid 27387172)
19. Liu Y, Qin W, Hou S, et al. A-6G variant of the angiotensinogen gene and essential hypertension in Han, Tibetan, and Yi populations. Hypertens Res 2001; 24:159-163. (Pubitemid 32377587)
20. Kong XD, Yang YX, Zhang SZ, et al. Polymorphism of angiotensinogen gene and angiotensin converting enzyme gene in hypertension. Chin J Cardiol 2003; 31:735-738.
21. Wu SJ, Chiang FT, Chen WJ, et al. Three single-nucleotide polymorphisms of the angiotensinogen gene and susceptibility to hypertension: single locus genotype vs. haplotype analysis. Physiol Genomics 2004; 17:79-86. (Pubitemid 38924153)
22. Zhang Y, Chu SL, Shi JY, et al. Polymorphism of angiotensinogen gene are associated with plasma and uric aldosterone level in essential hypertensive patients. Molec Cardiol China 2006; 6:212-218.
23. Qi Y, Niu W, Zhou W, et al. Correlation between angiotensinogen gene polymorphisms and essential hypertension in Chinese population. J Hum Hypertens 2008; 22:147-150.
24. Jiang X, Sheng H, Li J, et al. Association between renin-angiotensin system gene polymorphism and essential hypertension: a community-based study. J Hum Hypertens 2009; 23:176-181.
25. Liu ZY, Liu LM. The study of angiotensinogen gene polymorphism by microchip electrophoresis. Chin Med J Metallurg Industry 2009; 26:502-504.
26. Niu W, Qi Y, Cen W, et al. Genetic polymorphisms of angiotensinogen and essential hypertension in a Tibetan population. Hypertens Res 2007; 30:1129-1137.
27. Wang Z, Zhao H, Yuan HL, et al. The association between the G-6A allele of angiotensinogen gene core promoter element 1 (AGCE1) and hypertension in Kazakans of Xinjiang. Chin J Cardiovasc Rev 2006; 4:464-466.
28. Yao CY, Yin XY, Wu LX. The association analysis between the A-6G allele of angiotensinogen gene core promoter element 1 (AGCE1) and hypertension in Bai ethnicities. J Pract Med 2010; 26:3514-3516.
29. Hu RL, Zhao SG, Niu GM, et al. Relationship between the mononucleotide polymorphism of angiotensinogen gene at 50 end promoter A-20C and A-6G and essential hypertension in Mongol nationality. J Clin Rehabil Tissue Eng Res 2007; 11:5865-5868. (Pubitemid 47433295)
30. Ying CQ, Wang YH, Wu ZL, et al. Association of the renin gene polymorphism, three angiotensinogen gene polymorphisms and the haplotypes with essential hypertension in the Mongolian population. Clin Exp Hypertens 2010; 32:293-300.
31. Wang T, Chen ZB, Jin SJ, Su QJ. Correlation between angiotensinogen gene and primary hypertension with cerebral infarction in the Li nationality of China. Neurosci Bull 2007; 23:287-292. (Pubitemid 350189503)
32. Kim HS, Lee G, John SW, Maeda N, Smithies O. Molecular phenotyping for analyzing subtle genetic effects in mice: application to an angiotensinogen gene titration. Proc Natl Acad Sci U S A 2002; 99:4602-4607. (Pubitemid 34286031)
33. Poon S, Goodman SG, Yan RT, et al. Bridging the gender gap: Insights from a contemporary analysis of sex-related differences in the treatment and outcomes of patients with acute coronary syndromes. Am Heart J 2012; 163:66-73.
34. Bugiardini R, Yan AT, Yan RT, et al. Canadian Acute Coronary Syndrome Registry I and II Investigators. Factors influencing underutilization of evidence-based therapies in women. Eur Heart J 2011; 32:1337-1344.
35. Xhyheri B, Bugiardini R. Diagnosis and treatment of heart disease: are women different from men? Prog Cardiovasc Dis 2010; 53:227-236.
36. Pizzi C, Bugiardini R. Further insights into syndrome X. Heart 2010; 96:1865-1867.
37. Tatu-Chitoiu G, Cinteza M, Dorobantu M, et al. In-hospital case fatality rates for acute myocardial infarction in Romania. CMAJ 2009; 180:1207-1213.
38. Bugiardini R, Estrada JL, Nikus K, Hall AS, Manfrini O. Gender bias in acute coronary syndromes. Curr Vasc Pharmacol 2010; 8:276-284.
39. Manfrini O, Bugiardini R. Barriers to clinical risk scores adoption. Eur Heart J 2007; 28:1045-1046. (Pubitemid 47343886)
40. Bedetti G, Pasanisi EM, Pizzi C, Turchetti G, LoréC. Economic analysis including long-term risks and costs of alternative diagnostic strategies to evaluate patients with chest pain. Cardiovasc Ultrasound 2008; 6:21.
41. Bugiardini R, Badimon L, Collins P, et al. Angina, ''normal'' coronary angiography, and vascular dysfunction: risk assessment strategies. PLoS Med 2007; 4:e12.
42. Bugiardini R. Women, 'non-specific' chest pain, and normal or near-normal coronary angiograms are not synonymous with favourable outcome. Eur Heart J 2006; 27:1387-1389. (Pubitemid 43998066)
43. Manfrini O, Bazzocchi G, Luati A, Borghi A, Monari P, Bugiardini R. Coronary spasm reflects inputs from adjacent esophageal system. Am J Physiol Heart Circ Physiol 2006; 290:H2085-H2091.
44. Bugiardini R. Normal coronary arteries: clinical implications and further classification. Herz 2005; 30:3-7. (Pubitemid 40521551)
45. Manfrini O, Morgagni G, Pizzi C, Fontana F, Bugiardini R. Changes in autonomic nervous system activity: spontaneous versus balloon-induced myocardial ischaemia. Eur Heart J 2004; 25:1502-1508.
46. Manfrini O, Pizzi C, Morgagni G, Fontana F, Bugiardini R. Effect of pravastatin on myocardial perfusion after percutaneous transluminal coronary angioplasty. Am J Cardiol 2004; 93:1391-1393. (Pubitemid 38692468)
47. Manfrini O, Pizzi C, Trerè D, Fontana F, Bugiardini R. Parasympathetic failure and risk of subsequent coronary events in unstable angina and non- ST-segment elevation myocardial infarction. Eur Heart J 2003; 24:1560-1566. (Pubitemid 37012190)
48. Bugiardini R, Galvani M, Ferrini D, et al. Effects of iloprost, a stable prostacyclin analog, on exercise capacity and platelet aggregation in stable angina pectoris. Am J Cardiol 1986; 58:453-459. (Pubitemid 16052672)
49. Bugiardini R, Galvani M, Ferrini D, et al. Myocardial ischemia induced by prostacyclin and iloprost. Clin Pharmacol Ther 1985; 38:101-108. (Pubitemid 15242208)
50. Schillaci G, De Vuono S, Pucci G. An endogenous brake on the sympathetic nervous system: the emerging role of catestatin in hypertension. J Cardiovasc Med (Hagerstown) 2011; 12:609-612.
51. Meng L, Ye XJ, Ding WH, et al. Plasma catecholamine release-inhibitory peptide catestatin in patients with essential hypertension. J Cardiovasc Med (Hagerstown) 2011; 12:643-647.
52. Al-Baba B. Resistant systemic hypertension. J Cardiovasc Med (Hagerstown) 2011; 12:340-342.
53. Demarie D, Marletta G, Imazio M, et al. Cardiovascular-associated disease in an addicted population: an observation study. J Cardiovasc Med (Hagerstown) 2011; 12:51-54.
54. Metra M, Zacà V, Parati G, et al., Heart Failure Study Group of the Italian Society of Cardiology. Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure. J Cardiovasc Med (Hagerstown) 2011; 12:76-84.
55. Lazzeri C, Valente S, Chiostri M, Picariello C, Gensini GF.Microalbuminuria in hypertensive nondiabetic patients with ST elevation myocardial infarction. J Cardiovasc Med (Hagerstown) 2010; 11:748-753.
56. Milei J. A cornerstone in the history of hypertension: the seventieth anniversary of the discovery of angiotensin. J Cardiovasc Med (Hagerstown) 2010; 11:260-264.